Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12046453 | 0.92 | HSP90AA1 (0.34) | HSP90AA1HSP90AB1 | |
| SCHEMBL1344457 | 0.84 | HSP90AA1 (0.32) | HSP90AA1HSP90AB1ALDH1A1TP53KMT2A | |
| SCHEMBL1148835 | 0.83 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1ALDH1A1MEN1NPC1 | |
| SCHEMBL2517374 | 0.83 | HSP90AA1 (0.33) | HSP90AA1HSP90AB1ALDH1A1MEN1NPC1 | |
| SCHEMBL1147883 | 0.82 | HSP90AA1 (0.37) | HSP90AA1HSP90AB1ALDH1A1LMNAALOX12 | |
| SCHEMBL14609804 | 0.77 | GABRA1 (0.40) | HSP90AA1HSP90AB1ALDH1A1MEN1LMNA | |
| SCHEMBL14609914 | 0.77 | ALDH1A1 (0.34) | HSP90AA1HSP90AB1ALDH1A1MEN1NPC1 | |
| SCHEMBL1148531 | 0.75 | CHEK1 (0.34) | HSP90AA1HSP90AB1ALDH1A1LMNAALOX12 | |
| SCHEMBL1148555 | 0.74 | HSP90AA1 (0.37) | HSP90AA1HSP90AB1ALDH1A1MEN1NPC1 | |
| SCHEMBL1148822 | 0.73 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-8969396-B2 | Method for treating a B-raf associated cancer with an Hsp90 inhibitor | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969396-B2 | Method for treating a B-raf associated cancer with an Hsp90 inhibitor | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8921407-B2 | Pyrazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921407-B2 | Pyrazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20100069442-A1 | PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20100069442-A1 | PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-03-18 | — | — | US | disclosed |
| US-7608635-B2 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608635-B2 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20070191445-A1 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-08-16 | — | — | US | disclosed |
| US-20070191445-A1 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191445-A1 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885ALDH1A1 1618/4885 |
| US-20100069442-A1 | PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885ALDH1A1 1744/4885 |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885ALDH1A1 1385/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885ALDH1A1 1036/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885ALDH1A1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.